Management of hepatic complications in HIV-infected persons (Q37151303)

18 August 2017

1 reference

title

Management of hepatic complications in HIV-infected persons (English)

1 reference

18 August 2017

0 references

1

Mark S Sulkowski

1 reference

PubMed ID

18447614

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

Journal of Infectious Diseases

18 August 2017

1 reference

18 August 2017

197 Suppl 3

1 reference

18 August 2017

S279-93

1 reference

18 August 2017

1 reference

Candidates for therapy: HBV.

21 January 2018

1 reference

Epidemiology of viral hepatitis and HIV co-infection

21 January 2018

1 reference

Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects

21 January 2018

1 reference

Screening for and treating hepatitis B virus in patients with HIV infection

21 January 2018

1 reference

Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy

21 January 2018

1 reference

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

21 January 2018

1 reference

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

21 January 2018

1 reference

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

21 January 2018

1 reference

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

21 January 2018

1 reference

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

21 January 2018

1 reference

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

21 January 2018

1 reference

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

21 January 2018

1 reference

Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy

21 January 2018

1 reference

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection

21 January 2018

1 reference

Clinical presentation and course of acute hepatitis C infection in HIV-infected patients

21 January 2018

1 reference

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients

21 January 2018

1 reference

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

Rapid and early virological response to chronic hepatitis C treatment with IFN 2b or PEG-IFN 2b plus ribavirin in HIV/HCV co-infected patients

21 January 2018

1 reference

Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes

21 January 2018

1 reference

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients

21 January 2018

1 reference

Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients

21 January 2018

1 reference

Nucleoside analogues and mitochondrial toxicity

21 January 2018

1 reference

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons

21 January 2018

1 reference

Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial

21 January 2018

1 reference

Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic

21 January 2018

1 reference

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C.

21 January 2018

1 reference

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

21 January 2018

1 reference

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

21 January 2018

1 reference

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

Antiretroviral drug toxicity -- a challenge for the hepatologist?

21 January 2018

1 reference

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients

21 January 2018

1 reference

Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus

21 January 2018

1 reference

Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients

21 January 2018

1 reference

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

21 January 2018

1 reference

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

21 January 2018

1 reference

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

21 January 2018

HIV-protease inhibitors

1 reference

Liver toxicity caused by nevirapine

21 January 2018

1 reference

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function

21 January 2018

1 reference

Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.

21 January 2018

1 reference

Liver failure after long-term nucleoside antiretroviral therapy

21 January 2018

1 reference

The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection

21 January 2018

1 reference

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine

21 January 2018

1 reference

Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?

21 January 2018

1 reference

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

21 January 2018

1 reference

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART

21 January 2018

1 reference

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/533414

1 reference

18 August 2017

1 reference

PubMed ID

18447614